| A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | Durvalumab | Phase 2 | Not yet recruiting | AstraZeneca | 2026-11-17 |
| PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes | Durvalumab | Phase 2 | Not yet recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2026-11-16 |
| A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig | Atezolizumab | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 2026-11-10 |
| Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome | Atezolizumab, Cosibelimab | Phase 1 | Not yet recruiting | City of Hope Medical Center | 2026-11-09 |
| Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | Adebrelimab | Phase 2 | Not yet recruiting | Qun Zhao | 2026-11-09 |
| Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ | Adebrelimab | Phase 2 | Not yet recruiting | Fudan University | 2026-11-03 |
| A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) | Durvalumab | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 2026-11-02 |
| A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy | Durvalumab | Phase 2 | Recruiting | Samsung Medical Center | 2026-11-02 |
| Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer | Adebrelimab | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 2026-11-02 |
| Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer | Adebrelimab | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 2026-10-30 |
| Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma | Atezolizumab, Durvalumab | — | Not yet recruiting | Assiut University | 2026-10-29 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer | Atezolizumab | Phase 2 | Not yet recruiting | AbbVie | 2026-10-26 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer | Atezolizumab | Phase 2 | Not yet recruiting | AbbVie | 2026-10-26 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer | Adebrelimab | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-10-26 |
| A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC | Adebrelimab | Phase 3 | Not yet recruiting | West China Hospital | 2026-10-26 |
| A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC | Adebrelimab | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 2026-10-23 |
| A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents | Adebrelimab | Phase 1 / Phase 2 | Enrolling by invitation | Second Affiliated Hospital of Wenzhou Medical University | 2026-10-22 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer | Atezolizumab, Durvalumab | Phase 2 | Recruiting | Samsung Medical Center | 2026-10-21 |
| GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study) | Durvalumab | — | Not yet recruiting | AstraZeneca | 2026-10-20 |
| A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. | Durvalumab | Phase 3 | Recruiting | AstraZeneca | 2026-10-16 |
| Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia | Atezolizumab | — | Recruiting | Fundación Santa Fe de Bogota | 2026-10-02 |
| First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain | Avelumab | — | Active, not recruiting | Bristol-Myers Squibb | 2026-10-01 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A) | Envafolimab | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 2026-10-01 |
| Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma | Atezolizumab | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 2026-09-23 |
| SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC | Envafolimab | Phase 2 | Not yet recruiting | The First People's Hospital of Lianyungang | 2026-09-14 |
| Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion | Envafolimab | Not applicable | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 2026-07-30 |
| A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy. | Envafolimab | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 2026-07-27 |
| Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC | Sugemalimab | Phase 2 | Active, not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-07-17 |
| Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer | Envafolimab | Phase 1 / Phase 2 | Recruiting | West China Hospital | 2026-06-09 |
| Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies | Envafolimab | Phase 2 | Not yet recruiting | Sir Run Run Shaw Hospital | 2026-05-20 |
| Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program | Envafolimab | — | Recruiting | IR INNOVATE RESEARCH PRIVATE LIMITED | 2026-05-01 |
| Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment | Envafolimab | Phase 2 | Recruiting | Jian Li | 2026-04-30 |
| Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma | Avelumab | Phase 2 | Not yet recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 2026-03-10 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy | Cosibelimab | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 2026-02-23 |
| Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC | Sugemalimab | Not applicable | Recruiting | Peking Union Medical College | 2025-11-25 |
| Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC | Avelumab | Phase 2 | Recruiting | Samsung Medical Center | 2025-11-06 |
| Impact of Circadian Rhythm on Immunotherapy | Avelumab | Phase 2 | Recruiting | Liza Villaruz, MD | 2025-11-05 |
| Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial | Sugemalimab | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 2025-09-24 |
| DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma | Avelumab | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-08-07 |
| Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer | Sugemalimab | — | Not yet recruiting | Ji Yongling | 2025-06-25 |
| Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients | Sugemalimab | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 2025-05-23 |
| Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma | Cosibelimab | Phase 1 | Not yet recruiting | Arsen Osipov | 2025-05-21 |
| Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer | Avelumab | Phase 2 | Recruiting | Queen Mary University of London | 2025-03-25 |
| Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. | Avelumab | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 2025-03-11 |
| Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy | Sugemalimab | — | Recruiting | Peking University Cancer Hospital & Institute | 2025-03-11 |
| DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. | Avelumab | Phase 4 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2025-02-11 |
| A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | Sugemalimab | Phase 3 | Recruiting | Akeso | 2024-09-27 |
| Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer | Socazolimab | Phase 3 | Recruiting | Lee's Pharmaceutical Limited | 2024-06-14 |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | Sugemalimab | Phase 1 / Phase 2 | Recruiting | Sichuan University | 2024-01-22 |
| Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma | Bintrafusp alfa | Phase 2 | Active, not recruiting | Institut Bergonié | 2021-05-05 |
| Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | Bintrafusp alfa | Phase 1 | Active, not recruiting | M.D. Anderson Cancer Center | 2021-01-13 |
| TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY | Bintrafusp alfa | Not applicable | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2020-07-22 |
| Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma | Bintrafusp alfa | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 2020-06-05 |
| A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | Danburstotug | Phase 2 | Active, not recruiting | ImmuneOncia Therapeutics Inc. | 2020-06-04 |
| Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | Bintrafusp alfa | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | 2020-01-22 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Cosibelimab | Phase 1 | Active, not recruiting | Checkpoint Therapeutics, Inc. | 2017-07-11 |